


Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1. (Previously presented) A pharmaceutical composition comprising:

(a) a compound of the formula:



or an acid addition salts thereof,

wherein

the carbon atom designated * constitutes a center of chirality,

R⁴ is hydrogen or -(C=O)-R¹²;

each of R¹ and R¹², independently of each other, is alkyl of 1 to 6 carbon atoms,

phenyl, benzyl, pyridyl methyl, pyridyl, imidazolyl, imidazolylmethyl, or

CHR^{*}(CH₂)_nNR^{*}R⁰

wherein R^{*} and R⁰, independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or imidazolylmethyl, and n = 0, 1, 2;

R⁵ is C=O, CH₂, -CH₂-CO-, or SO₂;

each of R⁶ and R⁷, independently of the other, is nitro, cyano, trifluoromethyl,

carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxyl,

carboxyl, hydroxyl, amino, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon

atoms, cycloalkoxy of 3 to 8 carbon atoms, halo, bicycloalkyl of up to 18

carbon atoms, tricycloalkoxy of up to 18 carbon atoms, 1-indanyloxy, 2-

indanyloxy, C₄-C₈-cycloalkylidenemethyl, or C₃-C₁₀-alkylidenemethyl; and

each of R⁸, R⁹, R¹⁰, and R¹¹ independently of the others, is

(i) hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy,


carbopropoxy, acetyl, carbamoyl, acetoxyl, carboxyl, hydroxyl, amino,

- alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halo, or
- (ii) one of R^8 , R^9 , R^{10} , and R^{11} is acylamino comprising a lower alkyl, and the remaining of R^8 , R^9 , R^{10} , and R^{11} are hydrogen, or
- (iii) hydrogen if R^8 and R^9 taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (iv) hydrogen if R^{10} and R^{11} , taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (v) hydrogen if R^9 and R^{10} taken together are benzo; and
- (b) a pharmaceutically acceptable carrier.

2-4. (Canceled).

5. (Currently amended) A pharmaceutical composition comprising:

(a) a compound of the formula:



or an acid addition salt thereof,

in which

the carbon atom designated * constitutes a center of chirality;

R^4 is hydrogen or $-(C=O)-R^{12}$, where

each of R^1 and R^{12} , independently of each other, is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl, pyridyl methyl, imidazolyl, imidazolylmethyl, or $CHR^*(CH_2)_nNR^0R^0$

wherein R^* and R^0 , independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or imidazolylmethyl, and $n = 0, 1, 2$;

R⁵ is C=O or CH₂;

each of R⁶ and R⁷, independently of the other is alkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms; C₄-C₆-cycloalkylidenemethyl, C₂-C₁₀-alkylidenemethyl, C₆-C₁₈-bicycloalkoxy, C₆-C₁₈-tricycloalkoxy, 1-indanyloxy, or 2-indanyloxy;

each of R⁸, R⁹, R¹⁰, and R¹¹, independently of the others, is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, halo, carbamoyl, acetoxymethyl, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, and alkoxy of 1 to 10 carbon atoms; and

(b) a pharmaceutically acceptable carrier.

6-18. (Canceled).

19. (Previously presented) The pharmaceutical composition of claim 1, wherein said compound is a substantially chirally pure (R)-isomer or a substantially chirally pure (S)-isomer.

20-29. (Canceled).

30. (Previously presented) The pharmaceutical composition of claim 5, wherein said compound is a substantially chirally pure (R)-isomer or a substantially chirally pure (S)-isomer.

31-40. (Canceled).

41. (Currently amended) The pharmaceutical composition of claim 1 or 5, wherein the compound is ~~(3-(1,3-dioxoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) propanoate~~ (3-(1,3-dioxoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) propanoate; (3-(1,3-dioxoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) acetate; (3-(1,3-dioxoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) pentanoate; (3-(1,3-dioxoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) benzoate; (3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1-

oxoisindolin-2-yl)propanoylamino) acetate; (3-[4-(acetylamino)-1,3-dioxoisindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl) propanoylamino)acetate; (3-(3-ethoxy-4-methoxyphenyl)-3-(4-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; (3-(3-ethoxy-4-methoxyphenyl)-3-(5-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; (3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(4-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; (3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(5-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; ~~N-acetyl-(3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(5-methyl-1,3-dioxoisindolin-2-yl)propanoylamino) acetate~~ N-acetyl-(3-(3-ethoxy-4-methoxyphenyl)-3-(5-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; N-acetyl-(3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(4-methyl-1,3-dioxoisindolin-2-yl)propanoylamino) acetate; (3-[5-(acetylamino)-1,3-dioxoisindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propanoylamino)acetate; (3-(1,3-dioxobenzo[e]isindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino)acetate; (3-(3-ethoxy-4-methoxyphenyl)-3-phthalimido-propanoylamino)pyridine-3-carboxylate; (3-[4-(acetylamino)-1,3-dioxoisindolin-2-yl]-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoylamino)acetate; (N-acetyl-3-[4-(acetylamino)-1,3-dioxoisindolin-2-yl]-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoylamino)acetate; or (3-(3-ethoxy-4-methoxyphenyl)-3-(1-oxoisindolin-2-yl)propanoylamino)acetate.

42. (Previously presented) The pharmaceutical composition of claim 41, wherein the compound is a substantially chirally pure (R)-isomer or a substantially chirally pure (S)-isomer.